- Home
- SVRA vs AZTA Comparison
SVRA vs AZTA Comparison
Compare SVRA & AZTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SVRA | AZTA |
|---|---|---|
| Founded | 2007 | 1978 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.4B |
| IPO Year | N/A | 1995 |
Fundamental Metrics
Financial Performance| Metric | SVRA | AZTA |
|---|---|---|
| Price | $5.83 | $35.13 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 5 |
| Target Price | $6.88 | ★ $43.60 |
| AVG Volume (30 Days) | ★ 2.2M | 631.9K |
| Earning Date | 11-12-2025 | 11-21-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $593,821,000.00 |
| Revenue This Year | N/A | $5.73 |
| Revenue Next Year | N/A | $4.40 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.89 | $23.91 |
| 52 Week High | $6.37 | $55.64 |
Technical Indicators
Market Signals| Indicator | SVRA | AZTA |
|---|---|---|
| Relative Strength Index (RSI) | 74.17 | 61.83 |
| Support Level | $5.09 | $28.83 |
| Resistance Level | $6.37 | $38.20 |
| Average True Range (ATR) | 0.39 | 1.41 |
| MACD | 0.15 | 0.51 |
| Stochastic Oscillator | 82.26 | 69.69 |
Price Performance
Historical ComparisonAbout SVRA Savara Inc.
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.
About AZTA Azenta Inc.
Azenta Inc is a provider of life sciences solutions, enabling impactful breakthroughs and therapies to market faster. It provides a full suite of reliable cold-chain sample management solutions and genomic services across areas such as drug development, clinical research and cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. The company has three reportable segments that are Sample Management Solutions, Multiomics, and B Medical Systems. It generates a substantial part of its revenue from its Sample Management Solutions segment.